XML 103 R89.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Schedule of Reconciliation of Adjusted EBITDA to Net Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Adjusted EBITDA [1] $ (80,371) $ (116,413) $ (121,589)
Share-based compensation expense [1],[2] (53,610) (62,908) (55,477)
Restructuring expense [1],[3] (2,004)   $ (2,023)
Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag     Restructuring expense
Impairment of long-lived assets (7,205) [1],[3] (25,429)  
Impairment of right-of-use and related long-lived assets [1],[4]   (25,429)  
Depreciation and amortization expense [1] (19,256) (22,231) $ (20,920)
Interest expense [1],[5] (11,580) (13,800) (4,238)
Interest and other income, net [1] 14,534 15,531 4,056
Net loss attributable to Adaptive Biotechnologies Corporation [1] (159,492) (225,250) (200,191)
Net loss attributable to noncontrolling interest [1] (103) (54) (177)
Net loss (159,595) (225,304) (200,368)
Operating Segments | MRD      
Segment Reporting Information [Line Items]      
Adjusted EBITDA [1] (41,223) (88,844) (60,496)
Share-based compensation expense [1],[2] (24,848) (28,321) (17,999)
Restructuring expense [1],[3] (1,272)    
Impairment of long-lived assets [1],[3] (2,819)    
Depreciation and amortization expense [1] (10,073) (9,225) (6,642)
Operating Segments | IM      
Segment Reporting Information [Line Items]      
Adjusted EBITDA [1] (26,005) (14,128) (45,654)
Share-based compensation expense [1],[2] (19,051) (22,930) (23,892)
Restructuring expense [1],[3] (732)    
Impairment of long-lived assets [1],[3] (4,386)    
Depreciation and amortization expense [1] (7,450) (10,436) (12,294)
Unallocated Corporate      
Segment Reporting Information [Line Items]      
Adjusted EBITDA [1] (13,143) (13,441) (15,439)
Share-based compensation expense [1],[2] (9,711) (11,657) (13,586)
Restructuring expense [1],[3]     $ (2,023)
Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag     Restructuring expense
Impairment of right-of-use and related long-lived assets [1],[4]   (25,429)  
Depreciation and amortization expense [1] (1,733) (2,570) $ (1,984)
Interest expense [1],[5] (11,580) (13,800) (4,238)
Interest and other income, net [1] 14,534 15,531 4,056
Net loss [1] $ (159,595) $ (225,304) $ (200,368)
[1] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.
[2] Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, Equity Incentive Plans for details on our share-based compensation expense.
[3] Represents expenses recognized in conjunction with restructuring activities. See Note 15, Restructurings for details on our restructuring expenses.
[4] Represents impairment costs for certain right-of-use and related long-lived assets. See Note 10, Leases for details on our impairment expense.
[5] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, Revenue Interest Purchase Agreement for details on the Purchase Agreement.